Ginkgo

October 2, 2020

Overview

Ginkgo is a large tree with fan-shaped leaves. It is native to China, Japan, and Korea, but is also now grown in Europe and the United States. The ginkgo tree is thought to be one of the oldest living trees, dating back to more than 200 million years.

Ginkgo leaf is often taken by mouth for memory and thought problems, anxiety, vision problems, and many other conditions, but there is no good scientific evidence to support most of these uses.

The list of other uses of ginkgo is very long. This may be because this herb has been around for so long. Ginkgo biloba is one of the longest living tree species in the world. Ginkgo trees can live as long as a thousand years. Using ginkgo for asthma and bronchitis was described in 2600 BCE.

In manufacturing, ginkgo leaf extract is used in cosmetics. In foods, roasted ginkgo seed, which has the pulp removed, is an edible delicacy in Japan and China.

Classification

Is a Form of:

Tree native to China, Japan and Korea

Primary Functions:

Memory and thought problems, anxiety

Also Known As:

Fossil Tree, Ginkgo biloba, Ginkgo Biloba Leaf, Ginkgo Extract, Ginkgo Folium

How Does It Work?

Ginkgo seems to improve blood circulation, which might help the brain, eyes, ears, and legs function better. It may act as an antioxidant to slow down Alzheimer's disease and interfere with changes in the brain that might cause problems with thinking.

Ginkgo seeds contain substances that might kill the bacteria and fungi that cause infections in the body. The seeds also contain a toxin that can cause serious side effects like seizures and loss of consciousness.

Uses

Anxiety. Research shows that taking a ginkgo extract for 4 weeks can reduce symptoms of anxiety.
Diseases, such as Alzheimer disease, that interfere with thinking (dementia). Taking 240 mg of ginkgo daily may slightly improve dementia symptoms. But it's unclear how ginkgo compares to conventional medicines used for dementia. Ginkgo doesn't seem to prevent dementia from developing or getting worse.
Premenstrual syndrome (PMS). Taking ginkgo leaf extract by mouth seems to relieve breast tenderness and other symptoms associated with PMS when started during the 16th day of the menstrual cycle and continued until the 5th day of the following cycle.
Schizophrenia. Research shows that taking ginkgo daily in addition to conventional antipsychotic medications for 8-16 weeks can reduce symptoms of schizophrenia. It may also reduce some side effects like thirst and constipation and adverse effects associated with the antipsychotic medication, haloperidol.
A movement disorder often caused by antipsychotic drugs (tardive dyskinesia). Tardive dyskinesia is a movement disorder that is caused by certain antipsychotic drugs. Research shows that taking a specific ginkgo extract (EGb 761, Yi Kang Ning, Yang Zi Jiang Pharmaceuticals Ltd.) for 12 weeks can reduce the severity of tardive dyskinesia symptoms in people with schizophrenia who are taking antipsychotic drugs.
Dizziness (vertigo). Taking ginkgo leaf extract by mouth seems to improve symptoms of dizziness and balance disorders.

Recommended Dosing

The following doses have been studied in scientific research:

BY MOUTH:

For anxiety: 80 mg or 160 mg of a ginkgo leaf extract called EGb 761 has been taken three times per day for 4 weeks.
For diseases, such as Alzheimer disease, that interfere with thinking (dementia): 60-480 mg per day of ginkgo leaf extract ,divided in two or three doses, has been taken for up to one year. The most commonly studied dose is 120-240 mg per day with 240 mg possibly being more effective. Most of the clinical studies on the effectiveness of ginkgo leaf for dementia have used the standardized extracts EGb 761 (Dr. Willmar Schwabe Pharmaceuticals and Ipsen) and LI 1370 (Lichtwer Pharma).
For dizziness (vertigo): 160 mg of a ginkgo leaf extract called EGb 761 has been taken once daily or in two divided doses daily for 3 months.
For premenstrual syndrome (PMS): 80 mg of a ginkgo leaf extract called EGb 761 has been taken twice daily, starting on the sixteenth day of the menstrual cycle until the fifth day of the next cycle. Also 40 mg of a ginkgo leaf extract called Ginko T.D. has been taken three times daily starting on the sixteenth day of the menstrual cycle until the fifth day of the next cycle.
For schizophrenia: 120-360 mg of a ginkgo leaf extract called EGb 761 (Yi Kang Ning, Yang Zi Jiang Pharmaceuticals Ltd., Jiangsu, China) has been used daily for 8-16 weeks.
For a movement disorder often caused by antipsychotic drugs (tardive dyskinesia): 80 mg of a ginkgo leaf extract called EGb 761, three times daily for 12 weeks, has been used.

For all uses, start at a lower dose of not more than 120 mg per day to avoid gastrointestinal (GI) side effects. Increase to higher doses indicated as needed. Dosing may vary depending on the specific formulation used. Most researchers used specific standardized Ginkgo biloba leaf extracts. Some people take 0.5 mL of a standard 1:5 tincture of the crude ginkgo leaf three times daily.

You should avoid crude ginkgo plant parts. These can contain dangerous levels of the toxic chemicals found in the seed of the plant and elsewhere. These chemicals can cause severe allergic reactions.

Ginkgo Supplements Frequently Asked Questions

What is ginkgo biloba good for?

People use it for a variety of reasons. The therapeutic properties of the ginkgo plant are said to include treatment for blood disorders and memory problems, enhancement of cardiovascular function and to improve eye health. Also known as the maidenhair tree, ginkgo is one of the oldest species of tree in the world.

Is Ginkgo biloba safe to take daily?

There is no standard dose of ginkgo biloba supplements. A common dose in people with dementia is 40 milligrams of that extract three times daily. For improving cognitive function in healthy people, studies have used between 120 milligrams to 600 milligrams of the extract daily.

Who should not take ginkgo biloba?

If you are older, have a bleeding disorder or are pregnant, don't take ginkgo. The supplement might increase your risk of bleeding. If you're planning to have surgery, stop taking ginkgo two weeks beforehand. Ginkgo might interfere with the management of diabetes.

Does Ginkgo biloba work sexually?

Ginkgo (Ginkgo biloba). Increases circulation and may improve sexual function, although one study found no effect. Helped men with ED improve sexual function, according to one double-blind study. People in the study took 2 weeks off after 8 weeks of treatment.

Should I take ginkgo at night?

When taken 30 - 60 minutes before bed, gingko biloba supplements have been shown to reduce stress and enhance relaxation. This will help you to relax after a long day and it may even contribute to improved sleep quality.

Can ginkgo cause stroke?

“Could ginkgo cause a stroke?” asks The Daily Mail today. During the study, seven people taking ginkgo had strokes or warning strokes, compared with none in the placebo group. The study was too small reliably to demonstrate any effect that ginkgo may have on dementia.

What medications should not be taken with ginkgo biloba?

Blood-thinning medications -- Ginkgo has blood-thinning properties and therefore should not be used if you are taking anticoagulant (blood-thinning) medications, such as aspirin, clopidogrel (Plavix), dipyridamole (Persantine), heparin, ticlopidine (Ticlid), or warfarin (Coumadin).

Does Ginkgo biloba cause liver damage?

Gingko biloba consumption did not cause any negative changes in biomarkers of liver function, a new study found. It was motivated by two recent studies on rodents, which suggested that high doses of Gingko biloba leaf extract may increase risk of liver and thyroid cancer.

What is the best time to take ginkgo biloba?

Ginkgo biloba extract is made from dried leaves of the ancient ginkgo tree. Evidence suggests taking 250 mg of 30–60 minutes of Ginkgo biloba before bed may help reduce stress, enhance relaxation and promote sleep.

What are the side effects of taking ginkgo biloba?

It can cause some minor side effects such as stomach upset, headache, dizziness, constipation, forceful heartbeat, and allergic skin reactions. There is some concern that ginkgo leaf extract might increase the risk of liver and thyroid cancers.

Does Ginkgo biloba actually work?

Ginkgo's effect on memory enhancement has had conflicting results. While some evidence suggests that ginkgo extract might modestly improve memory in healthy adults, most studies indicate that ginkgo doesn't improve memory, attention or brain function.

When should you not take ginkgo biloba?

What is the best way to take ginkgo biloba?

Dosage and form

Ginkgo is available in capsule form, as tablets, liquid extracts, and dried leaf for teas. In studies, adults have used between 120 and 240 milligrams a day in divided doses. It appears to take 4 to 6 weeks before improvements are noticed.

How long can you take ginkgo?

For diseases, such as Alzheimer disease, that interfere with thinking (dementia): 60-480 mg per day of ginkgo leaf extract ,divided in two or three doses, has been taken for up to one year. The most commonly studied dose is 120-240 mg per day with 240 mg possibly being more effective.

Does Ginkgo raise blood pressure?

Medications for high blood pressure: Ginkgo may lower blood pressure, so taking it with blood pressure medications may cause blood pressure to drop too low. Medications to lower blood sugar: Ginkgo may raise or lower insulin levels and blood sugar levels.

Is Ginko safe?

When used orally in moderate amounts, ginkgo appears to be safe for most healthy adults. Ginkgo can cause: Headache. Dizziness.

Does Ginkgo biloba give you energy?

Some studies suggest that ginkgo biloba may improve some aspects of mood, including alertness and calmness, in healthy subjects. By making you more alert and calm, it may increase your sense of energy. Ginseng. This relatively safe and popular herb is said to reduce fatigue and enhance stamina and endurance.

Is Ginkgo biloba good for your memory?

Ginkgo biloba extract, derived from the leaves of the Ginkgo biloba tree, is often touted as a memory aid. But it appears unlikely that Ginkgo biloba extract can slow or prevent age-related memory problems, or memory loss associated with mild cognitive impairment or Alzheimer's disease.

Is Ginkgo biloba good for hair growth?

Ginkgo biloba has been proven to potentially help slow the hair loss process down and even promote new growth. It's important to note that most research that has been done has been on animals. Additional studies are needed to prove the effectiveness on humans.

Is Ginkgo biloba bad for your kidneys?

The Ginkgo biloba extract (GbE) protects the kidney from damage produced by a single and low dose of carbon tetrachloride in adult male rats.

Does Ginkgo biloba make you tired?

Should I take ginkgo biloba on an empty stomach?

Ginkgo Biloba Recommended Use:

Take 1 capsule with water or your favorite beverage twice daily on an empty stomach. Take first serving 30 minutes prior to breakfast, second 30 minutes prior to lunch.

Can I take ginkgo biloba and fish oil together?

Interactions between your drugs

No interactions were found between Fish Oil and Ginkgo Biloba. This does not necessarily mean no interactions exist. Always consult your healthcare provider.

Clinical Studies

^ a b c Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord. (2000)
^ a b c Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. J Neurol Sci. (2009)
^ a b Usai S, Grazzi L, Bussone G. Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up. Neurol Sci. (2011)
^ a b Usai S, et al. An innovative approach for migraine prevention in young age: a preliminary study. Neurol Sci. (2010)
^ a b Esposito M, Carotenuto M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol Sci. (2011)
^ a b Wu Y, et al. Ginkgo biloba extract improves coronary blood flow in patients with coronary artery disease: role of endothelium-dependent vasodilation. Planta Med. (2007)
^ a b Zhang WF, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. (2011)
^ a b Lyon MR, et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci. (2001)
^ a b Zhang ZJ, et al. Dietary supplement with a combination of Rhodiola crenulata and Ginkgo biloba enhances the endurance performance in healthy volunteers. Chin J Integr Med. (2009)
^ a b Nathan PJ, et al. Effects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humans. Hum Psychopharmacol. (2004)
^ a b Kennedy DO, Scholey AB, Wesnes KA. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutr Neurosci. (2001)
^ a b c Wesnes KA, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). (2000)
^ a b Wesnes KA, et al. The cognitive, subjective, and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints. Psychopharmacol Bull. (1997)
^ a b c Hartley DE, Elsabagh S, File SE. Gincosan (a combination of Ginkgo biloba and Panax ginseng): the effects on mood and cognition of 6 and 12 weeks' treatment in post-menopausal women. Nutr Neurosci. (2004)
^ a b Wu YZ, et al. Ginkgo biloba extract improves coronary artery circulation in patients with coronary artery disease: contribution of plasma nitric oxide and endothelin-1. Phytother Res. (2008)
^ a b Wu Y, et al. Ginkgo biloba extract improves coronary blood flow in healthy elderly adults: role of endothelium-dependent vasodilation. Phytomedicine. (2008)
^ a b c DeFeudis FV. A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry. (2003)
^ a b Ginkgos and People2014 A Thousand Years of Interaction.
^ Winslow LC, Kroll DJ. Herbs as medicines. Arch Intern Med. (1998)
^ Curtis-Prior P, Vere D, Fray P. Therapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. J Pharm Pharmacol. (1999)
^ a b Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. BMJ. (2001)
^ a b c Ekman L, et al. Development of an alternative method for determination of terpene lactones in ginkgo dry extract. Pharmeur Bio Sci Notes. (2009)
^ a b c d e f g h i [No authors listed. EGb 761: ginkgo biloba extract, Ginkor. Drugs R D. (2003)
^ Kaur P, et al. Optimization of extraction technique and validation of developed RP-HPLC-ELSD method for determination of terpene trilactones in Ginkgo biloba leaves. J Pharm Biomed Anal. (2009)
^ a b Vitolo O, et al. Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J. Neurobiol Aging. (2009)
^ Bolshakov S, et al. A concise synthesis of ginkgolide M, a minor component of a terpene trilactone fraction from ginkgo biloba roots. J Nat Prod. (2006)
^ Scholtyssek H, et al. Antioxidative activity of ginkgolides against superoxide in an aprotic environment. Chem Biol Interact. (1997)
^ a b c d e f Liao HJ, et al. Two new ginkgolides from the leaves of Ginkgo biloba. Planta Med. (2011)
^ Liu ZH, Zeng S. Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes. Toxicol Lett. (2009)
^ a b c d e f g h i j k Chemical analysis of Ginkgo biloba leaves and extracts.
^ Extraction and isolation of shikimic acid from Ginkgo biloba leaves utilizing an ionic liquid that dissolves cellulose.
^ a b Qaâdan F, et al. Polyphenols from Ginkgo biloba. Sci Pharm. (2010)
^ Stafford HA, Kreitlow KS, Lester HH. Comparison of Proanthocyanidins and Related Compounds in Leaves and Leaf-Derived Cell Cultures of Ginkgo bioloba L., Pseudotsuga menziesii Franco, and Ribes sanguineum Pursh. Plant Physiol. (1986)
^ a b Sloley BD, et al. Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm Pharmacol. (2000)
^ Briançon-Scheid F, Lobstein-Guth A, Anton R. HPLC Separation and Quantitative Determination of Biflavones in Leaves from Ginkgo biloba. Planta Med. (1983)
^ Hyun SK, et al. Biflavone glucosides from Ginkgo biloba yellow leaves. Chem Pharm Bull (Tokyo). (2005)
^ Expression of Chlorophyllase Is Not Induced during Autumnal Yellowing in Ginkgo biloba.
^ Huang X, Xie W, Gong Z. Characteristics and antifungal activity of a chitin binding protein from Ginkgo biloba. FEBS Lett. (2000)
^ Hauns B, et al. Phase II study with 5-fluorouracil and ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancer. Arzneimittelforschung. (1999)
^ a b c d e Meston CM, Rellini AH, Telch MJ. Short- and long-term effects of Ginkgo biloba extract on sexual dysfunction in women. Arch Sex Behav. (2008)
^ a b c d e f g h i j Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry. (2003)
^ a b c d Kehr J, et al. Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®. Int Psychogeriatr. (2012)
^ Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. (2009)
^ a b c Diamond BJ, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil. (2000)
^ a b c d Das A, et al. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav. (2002)
^ a b c d e Woelkart K, et al. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res. (2010)
^ The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba.
^ Self-Emulsifying Drug Delivery Systems for Improving Oral Absorption of Ginkgo Biloba Extracts.
^ Oliveira EJ, Watson DG. In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes. FEBS Lett. (2000)
^ a b c d Lau AJ, et al. Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J Pharmacol Exp Ther. (2010)
^ a b c Deng Y, et al. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica. (2008)
^ Blonk M, et al. Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers. Antimicrob Agents Chemother. (2012)
^ Wiegman DJ, Brinkman K, Franssen EJ. Interaction of Ginkgo biloba with efavirenz. AIDS. (2009)
^ Naccarato M, Yoong D, Gough K. A Potential Drug-Herbal Interaction between Ginkgo biloba and Efavirenz. J Int Assoc Physicians AIDS Care (Chic). (2012)
^ Guo CX, et al. Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica. (2012)
^ Kim BH, et al. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther. (2010)
^ Kim TE, et al. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. Clin Ther. (2009)
^ Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol. (2006)
^ Jiang X, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. (2005)
^ a b Janssens D, et al. Protection of mitochondrial respiration activity by bilobalide. Biochem Pharmacol. (1999)
^ Janssens D, et al. Protection of hypoxia-induced ATP decrease in endothelial cells by ginkgo biloba extract and bilobalide. Biochem Pharmacol. (1995)
^ Du G, et al. EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenation. Free Radic Biol Med. (1999)
^ Eckert A, et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry. (2003)
^ Janssens D, et al. Protection by bilobalide of the ischaemia-induced alterations of the mitochondrial respiratory activity. Fundam Clin Pharmacol. (2000)
^ Janssens D, et al. Effect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cells. Br J Pharmacol. (2000)
^ Sastre J, et al. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med. (1998)
^ Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine. (2005)
^ Bazan NG. The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Prog Brain Res. (1998)
^ Akisü M, et al. Platelet-activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo biloba extract reduce PAF concentration in the brain. Biol Neonate. (1998)
^ White HL, Scates PW, Cooper BR. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci. (1996)
^ Wu WR, Zhu XZ. Involvement of monoamine oxidase inhibition in neuroprotective and neurorestorative effects of Ginkgo biloba extract against MPTP-induced nigrostriatal dopaminergic toxicity in C57 mice. Life Sci. (1999)
^ a b c d Fehske CJ, Leuner K, Müller WE. Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res. (2009)
^ a b c d e f g Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol. (2010)
^ Watanabe CM, et al. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci U S A. (2001)
^ a b c Augustin S, et al. Gene Regulatory Effects of Ginkgo biloba Extract and Its Flavonol and Terpenelactone Fractions in Mouse Brain. J Clin Biochem Nutr. (2009)
^ Kuchler-Bopp S, et al. Receptor-mediated endocytosis of transthyretin by ependymoma cells. Brain Res. (2000)
^ Tsuzuki K, et al. Transthyretin binds amyloid beta peptides, Abeta1-42 and Abeta1-40 to form complex in the autopsied human kidney - possible role of transthyretin for abeta sequestration. Neurosci Lett. (2000)
^ a b c Ramassamy C, et al. The Ginkgo biloba extract, EGb761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. J Pharm Pharmacol. (1992)
^ a b c d e Yeh KY, et al. Ginkgo biloba extract enhances noncontact erection in rats: the role of dopamine in the paraventricular nucleus and the mesolimbic system. Neuroscience. (2011)
^ Ramassamy C, et al. Prevention by Ginkgo biloba extract (EGb 761) and trolox C of the decrease in synaptosomal dopamine or serotonin uptake following incubation. Biochem Pharmacol. (1992)
^ Ramassamy C, et al. Ginkgo biloba extract EGb 761 or trolox C prevent the ascorbic acid/Fe2+ induced decrease in synaptosomal membrane fluidity. Free Radic Res Commun. (1993)
^ Dillon KA, et al. Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Res. (1991)
^ Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol. (1994)
^ Bolaños-Jiménez F, et al. Stress-induced 5-HT1A receptor desensitization: protective effects of Ginkgo biloba extract (EGb 761). Fundam Clin Pharmacol. (1995)
^ Koyama T, et al. Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats. Neurosci Lett. (1999)
^ Izumi J, et al. Hippocampal serotonin 5-HT1A receptor enhances acetylcholine release in conscious rats. J Neurochem. (1994)
^ Lummis SC. 5-HT(3) receptors. J Biol Chem. (2012)
^ a b Thompson AJ, et al. Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. (2011)
^ Thompson AJ, Duke RK, Lummis SC. Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol. (2011)
^ a b Yamamoto Y, et al. Ginkgo biloba extract improves spatial memory in rats mainly but not exclusively via a histaminergic mechanism. Brain Res. (2007)
^ Chopin P, Briley M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology (Berl). (1992)
^ Jahanshahi M, Nickmahzar EG, Babakordi F. The effect of Ginkgo biloba extract on scopolamine-induced apoptosis in the hippocampus of rats. Anat Sci Int. (2013)
^ Jahanshahi M, et al. Protective effects of Ginkgo biloba extract (EGB 761) on astrocytes of rat hippocampus after exposure with scopolamine. Anat Cell Biol. (2012)
^ Lee TF, Chen CF, Wang LC. Effect of ginkgolides on beta-amyloid-suppressed acetylocholine release from rat hippocampal slices. Phytother Res. (2004)
^ Burns A, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. (2006)
^ Huang SH, et al. Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant alpha1beta2gamma2L GABA(A) receptors. Eur J Pharmacol. (2003)
^ Kamei C, Okumura Y, Tasaka K. Influence of histamine depletion on learning and memory recollection in rats. Psychopharmacology (Berl). (1993)
^ Kamei C, Chung YH, Tasaka K. Influence of certain H1-blockers on the step-through active avoidance response in rats. Psychopharmacology (Berl). (1990)
^ Schneider C, et al. Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Neurosci Lett. (1997)
^ Higuchi M, et al. Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience. (2000)
^ a b c d Tchantchou F, et al. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis. (2009)
^ Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. (2008)
^ Nakagawa S, et al. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci. (2002)
^ Chen YS, et al. Effect of bilobalide on peripheral nerve regeneration. Biomaterials. (2004)
^ Bruno C, et al. Regeneration of motor nerves in bilobalide-treated rats. Planta Med. (1993)
^ Effect of extract of leave Ginkgo Biloba on crushed sciatic nerve regeneration.
^ Jin GH, et al. Effects of Ginkgolide on the development of NOS and AChE positive neurons in the embryonic basal forebrain. Cell Biol Int. (2006)
^ a b Tchantchou F, et al. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J. (2007)
^ a b c Zhang XY, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry. (2012)
^ Egan MF, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. (2003)
^ Lee EJ, et al. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rats. J Neurosci Res. (2002)
^ Nada SE, Shah ZA. Preconditioning with Ginkgo biloba (EGb 761®) provides neuroprotection through HO1 and CRMP2. Neurobiol Dis. (2012)
^ Saleem S, et al. Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke. (2008)
^ Zhuang H, et al. Induction of heme oxygenase 1 by Ginkgo biloba in neuronal cultures and potential implications in ischemia. Cell Mol Biol (Noisy-le-grand). (2002)
^ Luo Y, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. (2002)
^ Sarris J, et al. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. (2011)
^ Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiatry. (2003)
^ Ward CP, et al. Ginkgo biloba extract: cognitive enhancer or antistress buffer. Pharmacol Biochem Behav. (2002)
^ a b Rapin JR, et al. Demonstration of the "anti-stress" activity of an extract of Ginkgo biloba (EGb 761) using a discrimination learning task. Gen Pharmacol. (1994)
^ Woelk H, et al. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. (2007)
^ Marcilhac A, et al. Effect of chronic administration of Ginkgo biloba extract or Ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sci. (1998)
^ a b Jezova D, et al. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers. J Physiol Pharmacol. (2002)
^ a b c Rojas P, et al. Antidepressant-like effect of a Ginkgo biloba extract (EGb761) in the mouse forced swimming test: role of oxidative stress. Neurochem Int. (2011)
^ Kamkaew N, et al. Bacopa monnieri Increases Cerebral Blood Flow in Rat Independent of Blood Pressure. Phytother Res. (2012)
^ a b Zhang SJ, Xue ZY. Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia. Asian Pac J Trop Med. (2012)
^ Mashayekh A, et al. Effects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot study. Neuroradiology. (2011)
^ Santos RF, et al. Cognitive performance, SPECT, and blood viscosity in elderly non-demented people using Ginkgo biloba. Pharmacopsychiatry. (2003)
^ Effects of Ginkgo Biloba Extract on a Cerebral Ischemia Model in Gerbils.
^ Ma S, et al. Neuroprotective effect of ginkgolide K against acute ischemic stroke on middle cerebral ischemia occlusion in rats. J Nat Med. (2012)
^ a b c Kuller LH, et al. Does Ginkgo biloba reduce the risk of cardiovascular events. Circ Cardiovasc Qual Outcomes. (2010)
^ Zeng X, et al. Ginkgo biloba for acute ischaemic stroke. Cochrane Database Syst Rev. (2005)
^ Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl). (2000)
^ Kennedy DO, et al. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers. Hum Psychopharmacol. (2007)
^ Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J Dev Behav Pediatr. (2002)
^ Cala S, Crismon ML, Baumgartner J. A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy. (2003)
^ Salehi B, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. (2010)
^ Niederhofer H. Ginkgo biloba treating patients with attention-deficit disorder. Phytother Res. (2010)
^ Sarris J, et al. Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder (ADHD): a systematic review of the evidence. Complement Ther Med. (2011)
^ a b c Brondino N, et al. A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. Evid Based Complement Alternat Med. (2013)
^ D'Andrea G, et al. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci. (2009)
^ Solomon PR, et al. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. (2002)
^ a b Elsabagh S, et al. Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers. Psychopharmacology (Berl). (2005)
^ Stough C, et al. Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. Int J Neuropsychopharmacol. (2001)
^ Rigney U, Kimber S, Hindmarch I. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res. (1999)
^ a b Kaschel R. Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers. Phytomedicine. (2011)
^ Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Int J Clin Pharmacol Res. (1984)
^ Canter PH, Ernst E. Ginkgo biloba is not a smart drug: an updated systematic review of randomised clinical trials testing the nootropic effects of G. biloba extracts in healthy people. Hum Psychopharmacol. (2007)
^ A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly.
^ Mix JA, Crews WD Jr. An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med. (2000)
^ Mix JA, Crews WD Jr. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol. (2002)
^ Bäurle P, Suter A, Wormstall H. Safety and effectiveness of a traditional ginkgo fresh plant extract - results from a clinical trial. Forsch Komplementmed. (2009)
^ Brautigam MR, et al. Treatment of age-related memory complaints with Ginkgo biloba extract: a randomized double blind placebo-controlled study. Phytomedicine. (1998)
^ Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry. (2000)
^ Vellas B, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. (2012)
^ a b DeKosky ST, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. (2008)
^ Snitz BE, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. (2009)
^ Kanowski S, et al. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. (1996)
^ a b c Herrschaft H, et al. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. (2012)
^ a b Ihl R, Tribanek M, Bachinskaya N; GOTADAY Study Group. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. (2012)
^ a b Le Bars PL, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. (1997)
^ McCarney R, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. (2008)
^ Gaus W. An example for an underpowered study: a comment on Ginkgo biloba for mild to moderate dementia in a community setting by McCarney et al. Int J Geriatr Psychiatry. (2009)
^ Ernst E. A comment on Ginkgo biloba for mild to moderate dementia in a community setting by McCarney et al. Int J Geriatr Psychiatry. (2009)
^ Hindmarch I. A comment on Ginkgo biloba for mild to moderate dementia in a community setting by McCarney et al. Int J Geriatr Psychiatry. (2009)
^ Napryeyenko O, Borzenko I; GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. (2007)
^ a b Yancheva S, et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health. (2009)
^ Murray BJ, Cowen PJ, Sharpley AL. The effect of Li 1370, extract of Ginkgo biloba, on REM sleep in humans. Pharmacopsychiatry. (2001)
^ Hemmeter U, et al. Polysomnographic effects of adjuvant ginkgo biloba therapy in patients with major depression medicated with trimipramine. Pharmacopsychiatry. (2001)
^ Rao SM, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. (1991)
^ Amato MP, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. (2001)
^ Lovera JF, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology. (2012)
^ Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. (1998)
^ Kuloglu M, et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. (2002)
^ Bilici M, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord. (2001)
^ a b Yao JK, et al. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res. (1998)
^ a b c d Atmaca M, et al. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci. (2005)
^ a b Zhang XY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. (2001)
^ a b c Doruk A, Uzun O, Ozşahin A. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. (2008)
^ Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed. Curr Opin Psychiatry. (2007)
^ Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. (2003)
^ Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res. (2005)
^ Nishio T, et al. Medial nigral dopamine neurons have rich neurotrophin support in humans. Neuroreport. (1998)
^ Tsai G, et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. (1998)
^ Altar CA, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. (1997)
^ Cheng B, Mattson MP. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res. (1994)
^ a b c Niederhofer H. First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder. Phytother Res. (2009)
^ Itil TM, et al. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull. (1998)
^ Akhondzadeh S, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev. (2008)
^ Hasanzadeh E, et al. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum Dev. (2012)
^ a b Campos-Toimil M, et al. Inhibition of type 4 phosphodiesterase by rolipram and Ginkgo biloba extract (EGb 761) decreases agonist-induced rises in internal calcium in human endothelial cells. Arterioscler Thromb Vasc Biol. (2000)
^ Campos-Toimil M, et al. Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells. Br J Pharmacol. (2008)
^ Ylä-Herttuala S, et al. Lipoproteins in normal and atherosclerotic aorta. Eur Heart J. (1990)
^ a b c Ou HC, et al. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol. (2009)
^ Chen XP, et al. Oxidized low density lipoprotein receptor-1 mediates oxidized low density lipoprotein-induced apoptosis in human umbilical vein endothelial cells: role of reactive oxygen species. Vascul Pharmacol. (2007)
^ Ou HC, et al. Ginkgo biloba extract attenuates oxLDL-induced endothelial dysfunction via an AMPK-dependent mechanism. J Appl Physiol. (2013)
^ Pierre SV, et al. The standardized Ginkgo biloba extract Egb-761 protects vascular endothelium exposed to oxidized low density lipoproteins. Cell Mol Biol (Noisy-le-grand). (2008)
^ Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. (2002)
^ de Winther MP, Hofker MH. Scavenging new insights into atherogenesis. J Clin Invest. (2000)
^ Macrophages lacking scavenger receptor A show a decrease in binding and uptake of acetylated low-density lipoprotein and of apoptotic thymocytes, but not of oxidatively damaged red blood cells.
^ Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest. (2009)
^ Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res. (2006)
^ Van Eck M, et al. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. (2005)
^ Sevov M, Elfineh L, Cavelier LB. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem Biophys Res Commun. (2006)
^ Anthocyanins Induce Cholesterol Efflux from Mouse Peritoneal Macrophages THE ROLE OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ-LIVER X RECEPTOR α-ABCA1 PATHWAY.
^ a b c d Tsai JY, et al. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res. (2010)
^ Wei JM, et al. Ginkgo suppresses atherosclerosis through downregulating the expression of connexin 43 in rabbits. Arch Med Sci. (2013)
^ Blackburn JP, et al. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. (1995)
^ Kwak BR, et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation. (2003)
^ Burnier L, et al. Intercellular communication in atherosclerosis. Physiology (Bethesda). (2009)
^ a b c d e Rodríguez M, et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis. (2007)
^ Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. (2005)
^ Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. (2005)
^ a b c Mansour SM, et al. Ginkgo biloba extract (EGb 761) normalizes hypertension in 2K, 1C hypertensive rats: role of antioxidant mechanisms, ACE inhibiting activity and improvement of endothelial dysfunction. Phytomedicine. (2011)
^ a b Kubota Y, et al. Effects of Ginkgo biloba extract feeding on salt-induced hypertensive Dahl rats. Biol Pharm Bull. (2006)
^ a b c d Kubota Y, et al. Effects of Ginkgo biloba extract on blood pressure and vascular endothelial response by acetylcholine in spontaneously hypertensive rats. J Pharm Pharmacol. (2006)
^ Romero JC, Reckelhoff JF. State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension. (1999)
^ Angiotensin II–mediated Hypertension in the Rat Increases Vascular Superoxide Production via Membrane NADH/NADPH Oxidase Activation.
^ Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. (1986)
^ Maxwell S, Greig L. Anti-oxidants-- a protective role in cardiovascular disease. Expert Opin Pharmacother. (2001)
^ Umegaki K, et al. Ginkgo biloba extract attenuates the development of hypertension in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol. (2000)
^ McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. (2001)
^ Auguet M, et al. Pharmacological bases of the vascular impact of Ginkgo biloba extract. Presse Med. (1986)
^ Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. (2006)
^ a b Koltermann A, et al. Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. (2007)
^ Keheyan G, Dunn LA, Hall WL. Acute effects of Ginkgo biloba extract on vascular function and blood pressure. Plant Foods Hum Nutr. (2011)
^ Suter A, Niemer W, Klopp R. A new ginkgo fresh plant extract increases microcirculation and radical scavenging activity in elderly patients. Adv Ther. (2011)
^ a b Mehlsen J, et al. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Funct Imaging. (2002)
^ a b c Boelsma E, et al. Evidence of the regulatory effect of Ginkgo biloba extract on skin blood flow and study of its effects on urinary metabolites in healthy humans. Planta Med. (2004)
^ Brinkley TE, et al. Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens. (2010)
^ Norgren L, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. (2007)
^ Hirsch AT, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. (2006)
^ Farah BQ, et al. Predictors of walking capacity in peripheral arterial disease patients. Clinics (Sao Paulo). (2013)
^ a b Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. (2000)
^ Bauer U. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforschung. (1984)
^ Peters H, Kieser M, Hölscher U. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial. Vasa. (1998)
^ Thomson GJ, et al. A clinical trial of Gingkco Biloba Extract in patients with intermittent claudication. Int Angiol. (1990)
^ Gardner CD, et al. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial. J Cardiopulm Rehabil Prev. (2008)
^ Mouren X, Caillard P, Schwartz F. Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPo2 determination. Angiology. (1994)
^ a b Moraga FA, et al. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile. Wilderness Environ Med. (2007)
^ a b c d Leadbetter G, et al. Ginkgo biloba does--and does not--prevent acute mountain sickness. Wilderness Environ Med. (2009)
^ Roncin JP, Schwartz F, D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med. (1996)
^ a b Gertsch JH, et al. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol. (2002)
^ a b Gertsch JH, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. (2004)
^ a b Chow T, et al. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. (2005)
^ a b Hsu CL, et al. Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: Role of heme oxygenase-1. Pulm Pharmacol Ther. (2009)
^ a b Liu XP, et al. Extract of Ginkgo biloba induces phase 2 genes through Keap1-Nrf2-ARE signaling pathway. Life Sci. (2007)
^ Chou PB, Morse CA. Understanding premenstrual syndrome from a Chinese medicine perspective. J Altern Complement Med. (2005)
^ Chou PB, Morse CA, Xu H. A controlled trial of Chinese herbal medicine for premenstrual syndrome. J Psychosom Obstet Gynaecol. (2008)
^ [Value of standardized Ginkgo biloba extract (EGb 761) in the management of congestive symptoms of premenstrual syndrome.
^ Ozgoli G, et al. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J Altern Complement Med. (2009)
^ a b Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther. (1998)
^ Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol. (2004)
^ Kang BJ, et al. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol. (2002)
^ Sintchak G, Geer JH. A vaginal plethysmograph system. Psychophysiology. (1975)
^ McKay D. Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev. (2004)
^ Sachs BD. Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal. Neurosci Biobehav Rev. (2000)
^ Sachs BD. Placing erection in context: the reflexogenic-psychogenic dichotomy reconsidered. Neurosci Biobehav Rev. (1995)
^ Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol. (2005)
^ Succu S, et al. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: Involvement of central oxytocin. Neuropharmacology. (2007)
^ Kippin TE, et al. Opposing roles of the nucleus accumbens and anterior lateral hypothalamic area in the control of sexual behaviour in the male rat. Eur J Neurosci. (2004)
^ Burnett AL, et al. Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol. (1997)
^ Kobayashi N, et al. Effect of leaves of Ginkgo biloba on hair regrowth in C3H strain mice. Yakugaku Zasshi. (1993)
^ General method for determining flavonoids in medicinal plants and raw cosmetics using HPLC with a photodiode array detector.
^ a b Chuarienthong P, Lourith N, Leelapornpisid P. Clinical efficacy comparison of anti-wrinkle cosmetics containing herbal flavonoids. Int J Cosmet Sci. (2010)
^ Ernst E, Stevinson C. Ginkgo biloba for tinnitus: a review. Clin Otolaryngol Allied Sci. (1999)
^ Han SS, et al. Clonazepam quiets tinnitus: a randomised crossover study with Ginkgo biloba. J Neurol Neurosurg Psychiatry. (2012)
^ Ernst E. Marketing studies and scientific research must be distinct. BMJ. (2001)
^ Hilton MP, Zimmermann EF, Hunt WT. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev. (2013)
^ Levene RZ. Low tension glaucoma: a critical review and new material. Surv Ophthalmol. (1980)
^ Park JW, et al. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean J Ophthalmol. (2011)
^ Quaranta L, et al. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. (2003)
^ [No authors listed. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. (1998)
^ Chung HS, et al. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther. (1999)
^ Wimpissinger B, et al. Influence of Ginkgo biloba on ocular blood flow. Acta Ophthalmol Scand. (2007)
^ Russo V, et al. Clinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitis. Eur J Ophthalmol. (2009)
^ a b Li XS, et al. Effect of Ginkgo leaf extract on vascular endothelial function in patients with early stage diabetic nephropathy. Chin J Integr Med. (2009)
^ Attia A, et al. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neurooncol. (2012)
^ Biggs ML, et al. Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study. Pharmacoepidemiol Drug Saf. (2010)
^ Ioannidis JP. Why most published research findings are false. PLoS Med. (2005)
^ Porter JM, et al. Evaluation and management of patients with Raynaud's syndrome. Am J Surg. (1981)
^ Raynaud's Phenomenon.
^ Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford). (2005)
^ Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. (2012)
^ Choi WS, et al. To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud's phenomenon in South Korea; Korean Raynaud study (KOARA study). Clin Rheumatol. (2009)
^ Whitton ME, et al. Interventions for vitiligo. Cochrane Database Syst Rev. (2006)
^ Porter J, et al. Response to cosmetic disfigurement: patients with vitiligo. Cutis. (1987)
^ Ongenae K, et al. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol. (2006)
^ Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy--evidence-based analysis of the literature. J Dtsch Dermatol Ges. (2007)
^ Szczurko O, et al. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med. (2011)
^ a b Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. (2003)
^ a b Kennedy DO, et al. Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine. Hum Psychopharmacol. (2007)
^ a b Scholey AB, Kennedy DO. Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand. Hum Psychopharmacol. (2002)
^ a b Kennedy DO, Scholey AB, Wesnes KA. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav. (2002)
^ Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily. Drugs R D. (2006)
^ Gardner CD, et al. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis. (2007)
^ Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. (1996)
^ Miller LG, Freeman B. Possible subdural hematoma associated with Ginkgo biloba. J Herb Pharmacother. (2002)
^ Spontaneous Hyphema Associated with Ingestion of Ginkgo biloba Extract.